Majority of IgAN investigations are in late-stage trials.

Majority of IgAN investigations are in late-stage trials.

Planned or ongoing clinical trials in IgAN.

Phase 0
1.1%

Phase I
17%

Phase I/II
2.2%

Phase II
35%

Phase II/III
3.4%

Phase III
21%

Phase IV
20%

Phase 0

Phase I

Phase I/II

Phase II

Phase II/III

Phase III

Phase IV